Description
## Why Three Receptors Change Everything
Most metabolic peptides work on one pathway. Retatrutide works on three — simultaneously.
Developed by Eli Lilly (compound code: LY3437943), Retatrutide is a first-in-class triple hormone receptor agonist that activates:
– **GLP-1 receptor** — reduces appetite, slows gastric emptying, and signals satiety to the brain
– **GIP receptor** — enhances insulin sensitivity and amplifies the GLP-1 response
– **Glucagon receptor** — directly accelerates fat oxidation and energy expenditure
The result is a synergistic metabolic effect that single or dual-receptor compounds cannot replicate.
—
## What the Research Data Shows
Retatrutide has been evaluated across Phase 1, 2, and 3 clinical trials involving thousands of participants. Key findings from peer-reviewed publications include:
– **17.5% average body weight reduction** at 24 weeks (Phase 2 trial, NEJM 2023)
– **24.4% average body weight reduction** at 48 weeks (Phase 2 trial)
– **22.8–24.2% body weight reduction** at 48 weeks with 8mg and 12mg doses (Nature Medicine 2024)
– **Up to 71.2 lbs average weight loss** reported in Phase 3 TRIUMPH-4 trial (Eli Lilly, December 2025)
– Significant reduction in liver fat in participants with metabolic dysfunction-associated steatotic liver disease
– Improvements in HbA1c levels, glycemic control, and kidney function markers
Phase 3 TRIUMPH program (5,800+ participants enrolled) is currently ongoing across multiple global sites.
—
## Mechanism: How Retatrutide Works
**Step 1 — Appetite Suppression via GLP-1**
GLP-1 receptor activation signals the hypothalamus to reduce hunger. Gastric emptying slows, food intake decreases, and the sensation of fullness extends significantly after meals.
**Step 2 — Metabolic Amplification via GIP**
GIP receptor activation enhances the body’s insulin sensitivity and works synergistically with GLP-1 to produce a stronger combined metabolic response than either receptor alone.
**Step 3 — Active Fat Oxidation via Glucagon**
Unlike GLP-1-only compounds, Retatrutide directly stimulates glucagon receptors — accelerating the breakdown and oxidation of stored fat tissue. This is the mechanism that drives superior body composition outcomes compared to dual-agonist compounds.
—
## Research Application & Dosing Reference
Based on Phase 2 and Phase 3 clinical trial protocols:
| Dose Level | Administration | Trial Phase |
|————|—————|————-|
| 2mg | Once weekly, subcutaneous | Starting / titration dose |
| 4mg | Once weekly, subcutaneous | Step-up week 4 |
| 6mg | Once weekly, subcutaneous | Step-up week 8 |
| 9mg | Once weekly, subcutaneous | Target maintenance dose |
| 12mg | Once weekly, subcutaneous | High-dose protocol |
*Dosing protocol sourced from published TRIUMPH Phase 3 trial design. All dosing information is provided for research reference purposes only.*
—
## Product Specifications
| Parameter | Details |
|———–|———|
| Compound | Retatrutide (LY3437943) |
| Presentation | Lyophilized powder |
| Vial content | 10mg |
| Purity | ≥98% (HPLC verified) |
| Storage | 2–8°C refrigerated; protect from light |
| Reconstitution | Bacteriostatic water recommended |
| Stability | 24 months lyophilized; use within 28 days once reconstituted |
| Usage | For research use only |
—
## Important Notice
This product is intended exclusively for licensed research and scientific study purposes. It is not approved for human therapeutic use by the FDA or any regulatory authority. Not for human consumption. Must be handled by qualified research professionals in appropriate laboratory settings.
